AMO Pharma in Collaboration with Population Health Research Institute (PHRI) and Venca Research Inc. Announces FDA Advice on Potential Phase 3 Development Path for AMO-02 in Treatment of Arrhythmogenic Cardiomyopathy (ACM)

The FDA provided non-binding advice on the design and potential primary endpoint for a Phase 3 study of AMO-02 in arrhythmogenic cardiomyopathy, giving AMO Pharma more clarity on a possible development path but not confirming a trial or future approval. The ongoing Phase 2 TaRGET study plans to recruit 120 patients at 17 Canadian sites, with first data expected in 2028; its primary endpoint differs from the endpoint discussed with the FDA.

Analysis

The useful signal is narrower than “FDA support”: the agency has indicated that clinically consequential arrhythmia events could support efficacy, but only “in principle,” and its advice is non-binding. This reduces uncertainty about what a later pivotal study might measure; it does not validate AMO-02, establish Phase 3 readiness, or imply a favorable review outcome.

The key development risk is the endpoint bridge. TaRGET’s primary endpoint is PVC change, whereas the discussed Phase 3 endpoint centers on ICD interventions and sustained symptomatic VT. A positive PVC result alone may therefore fail to establish that the drug reduces events patients experience. Event frequency, ICD programming and adjudication, follow-up duration, and the required sample size could make a pivotal trial longer or larger than the Phase 2 framing suggests. The secondary arrhythmia measures may become more decision-relevant than the stated primary endpoint, but their event counts and statistical power are not provided.

Timing limits tradability: first Phase 2 data are expected in 2028, leaving little near-term clinical evidence to reprice. AMO Pharma is private and no mapped public security offers direct exposure. Any spillover to ICD manufacturers is too indirect to support a directional trade. The contrarian read is modestly positive for regulatory path clarity, but the endpoint mismatch and long data wait dominate the investment case. Reassess only with trial results and evidence that clinically meaningful arrhythmia outcomes—not just PVC burden—move in the same direction.

Key Decisions for Investors

• No direct position: AMO Pharma is privately held, and this consultation announcement is not a clinical efficacy readout. Avoid treating it as a catalyst for public ICD makers or broad biotech exposure.
• Set a watch alert for TaRGET updates and the 2028 data readout. Verify PVC effect size, placebo separation, ICD-therapy and sustained-VT event counts, adverse events, and whether those secondary outcomes are sufficiently informative to support the endpoint bridge.
• Before underwriting a Phase 3 pathway, seek details on FDA feedback beyond the stated endpoint principle, including proposed event definitions, adjudication, follow-up, sample size, and operational feasibility. These are unreported and could materially alter time and cost to proof.
• Falsify the constructive view if Phase 2 shows PVC improvement without a consistent direction in clinically meaningful arrhythmia measures, or if subsequent FDA discussions do not support a feasible pivotal design.